Holen Sie sich die Stockscreener-App
26.27
0.30%
-0.065
Überblick
Nachrichten
Preisverlauf
Optionskette
Warum fällt PHG?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$26.34
Offen:
$26.425
24-Stunden-Volumen:
455.63K
Relative Volume:
0.42
Marktkapitalisierung:
$24.98B
Einnahmen:
$20.19B
Nettoeinkommen (Verlust:
$1.03B
KGV:
24.59
EPS:
1.0687
Netto-Cashflow:
$966.68M
1W Leistung:
-4.40%
1M Leistung:
-3.77%
6M Leistung:
-3.88%
1J Leistung:
+5.12%
1-Tages-Spanne:
$26.19
$26.52
1-Wochen-Bereich:
$25.10
$27.73
52-Wochen-Spanne:
$21.95
$33.44
Koninklijke Philips Nv Adr Stock (PHG) Company Profile
Firmenname
Koninklijke Philips Nv Adr
Sektor
Branche
Telefon
-
Adresse
-
Compare PHG vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
PHG
Koninklijke Philips Nv Adr
|
26.25 | 25.80B | 20.19B | 1.03B | 966.68M | 1.0687 |
ABT
Abbott Laboratories
|
89.81 | 163.10B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
301.86 | 123.10B | 25.12B | 3.25B | 4.28B | 8.3984 |
MDT
Medtronic Plc
|
80.53 | 105.15B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
57.22 | 86.87B | 20.62B | 3.56B | 3.66B | 2.3847 |
EW
Edwards Lifesciences Corp
|
84.09 | 47.44B | 6.30B | 1.07B | 1.34B | 1.8406 |
Koninklijke Philips Nv Adr Stock (PHG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-17 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-02-25 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2025-02-20 | Hochstufung | UBS | Neutral → Buy |
| 2024-10-29 | Hochstufung | Jefferies | Underperform → Hold |
| 2024-05-13 | Hochstufung | Bernstein | Mkt Perform → Outperform |
| 2024-05-07 | Hochstufung | Exane BNP Paribas | Underperform → Neutral |
| 2024-04-30 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2024-04-30 | Hochstufung | UBS | Sell → Neutral |
| 2024-02-07 | Herabstufung | Exane BNP Paribas | Outperform → Underperform |
| 2023-07-12 | Eingeleitet | Goldman | Buy |
| 2023-01-17 | Herabstufung | UBS | Neutral → Sell |
| 2022-10-18 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2022-10-14 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2022-09-12 | Hochstufung | Societe Generale | Hold → Buy |
| 2022-09-06 | Hochstufung | UBS | Sell → Neutral |
| 2022-07-25 | Herabstufung | Societe Generale | Buy → Hold |
| 2022-06-16 | Herabstufung | UBS | Neutral → Sell |
| 2022-01-20 | Herabstufung | Jefferies | Buy → Hold |
| 2022-01-14 | Hochstufung | HSBC Securities | Hold → Buy |
| 2022-01-12 | Herabstufung | Citigroup | Buy → Neutral |
| 2021-09-08 | Eingeleitet | Jefferies | Buy |
| 2021-07-08 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2021-06-21 | Herabstufung | HSBC Securities | Buy → Hold |
| 2021-03-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-07-28 | Eingeleitet | Societe Generale | Buy |
| 2019-07-30 | Eingeleitet | Citigroup | Buy |
| 2018-02-12 | Hochstufung | Berenberg | Hold → Buy |
| 2017-11-09 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2017-10-16 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2017-06-21 | Herabstufung | Natixis Bleichroeder | Buy → Neutral |
| 2017-04-25 | Herabstufung | Societe Generale | Buy → Hold |
| 2016-12-12 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2016-11-23 | Eingeleitet | Citigroup | Buy |
| 2016-05-11 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2016-03-01 | Hochstufung | HSBC Securities | Reduce → Hold |
| 2016-02-16 | Herabstufung | Jefferies | Hold → Underperform |
| 2015-11-27 | Eingeleitet | ING Group | Hold |
| 2015-09-08 | Eingeleitet | Credit Suisse | Outperform |
| 2015-08-27 | Hochstufung | Nomura | Neutral → Buy |
| 2015-07-28 | Hochstufung | Societe Generale | Hold → Buy |
| 2011-01-25 | Herabstufung | HSBC Securities | Overweight → Neutral |
| 2009-12-07 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2009-10-16 | Hochstufung | HSBC Securities | Neutral → Overweight |
| 2009-05-08 | Herabstufung | UBS | Buy → Neutral |
Alle ansehen
Koninklijke Philips Nv Adr Aktie (PHG) Neueste Nachrichten
Sleep Apnea Devices (Therapeutic, Diagnostic) Market Report 2026-2034 Featuring Key Players - GlobeNewswire Inc.
Sony Group Corp. ADR outperforms competitors despite losses on the day - MarketWatch
Sony Group Corp. ADR falls Thursday, underperforms market - MarketWatch
Philips launches new Bridge Plus Occlusion Balloon to help manage rare but life-threatening SVC tears during lead extraction - GlobeNewswire Inc.
Philips launches new Bridge Plus Occlusion Balloon to help manage rare but life-threatening SVC tears during lead extraction - Sahm
Philips receives FDA 510(k) clearance for its Rembra platform, expanding access to faster, more precise CT imaging across frontline care and cancer treatment planning - Finviz
Koninklijke Philips (ADR) stock (NL0000009538): Why Google Discover changes matter more now - AD HOC NEWS
Philips receives FDA 510(k) clearance for Verida, the world’s first AI-powered detector-based spectral CT*, advancing diagnostic precision across clinical applications - Sahm
Sony Group Corp. ADR rises Friday, still underperforms market - MarketWatch
Philips receives FDA 510(k) clearance for Verida, the world's first AI-powered detector-based spectral CT*, advancing diagnostic precision across clinical applications - Finviz
Sony Group Corp. ADR rises Wednesday, still underperforms market - MarketWatch
Koninklijke Philips (ADR) stock (NL0000009538): Why its focus on diagnostics and AI tools matters mo - AD HOC NEWS
Koninklijke Philips (ADR) stock (NL0000009538): Why its focus on healthcare innovation matters more - AD HOC NEWS
Koninklijke Philips N.V. (PHG) Stock Price, News, Quote & History - Yahoo! Finance Canada
MDIC appoints Philips Chief Medical Officer Carla Goulart Peron as new board member - Sahm
Sony Group Corp. ADR rises Wednesday, outperforms market - MarketWatch
FDA clears Philips AI solution that provides real-time guidance during complex minimally invasive heart valve repair - Finviz
Philips launches IntraSight Plus to simplify coronary interventions and advance precision care - Finviz
Philips remains No. 1 in Medtech at European Patent Office and the largest Dutch patent applicant - Sahm
Philips convenes the Annual General Meeting of Shareholders 2026 - Finviz
Philips proposes new appointment and re-appointments to its Supervisory Board and CEO re-appointment - Finviz
Sony Group Corp. ADR falls Wednesday, underperforms market - MarketWatch
Koninklijke Philips N.V. Stock (ISIN: NL0000009538) Holds Steady Amid Neutral Analyst Views and AI-D - AD HOC NEWS
Koninklijke Philips (ADR) Stock Gains Traction as Earnings Beat Expectations Amid Health Tech Recove - AD HOC NEWS
PHIA Stock Price and Chart — EURONEXT:PHIA - TradingView
Philips expands digital pathology portfolio with cloud-enabled Philips IntelliSite Pathology Solution on HealthSuite - Finviz
Philips connects patient monitoring and diagnostics to advance platform-based care intelligence at HIMSS26 - Finviz
Philips Sonicare unveils two new electric toothbrush ranges alongside refreshed brand direction - Finviz
Philips unveils Rembra CT at ECR 2026, setting a new benchmark for speed and patient access designed to support diagnostic confidence for acute and high-demand imaging environments - Finviz
SHERPA research consortium initiates seven clinical studies to validate AI-based assistive technologies for minimally invasive brain and cancer treatments - Finviz
Owlet Stock Before Q4 Earnings: Buy Now or Wait for Results? - Finviz
Philips introduces InkSpace Imaging's Snuggle flexible pediatric MRI coil for its 3.0T MR systems, helping to enhance imaging precision, efficiency and comfort - Finviz
Philips (PHG) Soars to 52-Week High on Strong Earnings, Upbeat Outlook - Finviz
SEISMIC consortium secures EUR 23.5 million IHI grant to pioneer next-generation minimally invasive brain treatments - Finviz
Earnings call transcript: Philips Q4 2025 earnings beat EPS forecasts - Investing.com
Philips proposes to re-appoint CEO Roy Jakobs - Finviz
PreciseOnco research consortium awarded EUR 14.9 million IHI grant to drive breakthroughs in precision cancer treatment - Finviz
Finanzdaten der Koninklijke Philips Nv Adr-Aktie (PHG)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.76%
0.37%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):